Rhumbline Advisers boosted its stake in AveXis, Inc. (NASDAQ:AVXS) by 234.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 22,682 shares of the company’s stock after buying an additional 15,901 shares during the period. Rhumbline Advisers owned approximately 0.08% of AveXis worth $1,864,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently modified their holdings of the company. Russell Investments Group Ltd. raised its holdings in AveXis by 41.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 24,871 shares of the company’s stock valued at $2,043,000 after buying an additional 7,321 shares during the period. Credit Suisse AG raised its holdings in AveXis by 36.4% in the 1st quarter. Credit Suisse AG now owns 63,228 shares of the company’s stock valued at $4,807,000 after buying an additional 16,876 shares during the period. Swiss National Bank raised its holdings in AveXis by 3.0% in the 1st quarter. Swiss National Bank now owns 27,400 shares of the company’s stock valued at $2,083,000 after buying an additional 800 shares during the period. Vanguard Group Inc. raised its holdings in AveXis by 11.7% in the 1st quarter. Vanguard Group Inc. now owns 1,194,809 shares of the company’s stock valued at $90,841,000 after buying an additional 124,750 shares during the period. Finally, Point72 Asset Management L.P. raised its holdings in AveXis by 32.8% in the 1st quarter. Point72 Asset Management L.P. now owns 717,514 shares of the company’s stock valued at $54,553,000 after buying an additional 177,114 shares during the period. Hedge funds and other institutional investors own 94.71% of the company’s stock.
Several analysts recently issued reports on the stock. Royal Bank Of Canada assumed coverage on shares of AveXis in a report on Thursday. They issued a “sector perform” rating and a $92.00 price objective on the stock. Zacks Investment Research upgraded shares of AveXis from a “sell” rating to a “hold” rating in a report on Thursday, September 7th. Barclays PLC assumed coverage on shares of AveXis in a report on Wednesday, September 6th. They issued an “overweight” rating and a $124.00 price objective on the stock. Wells Fargo & Company restated an “outperform” rating and issued a $134.00 price objective (up from $89.00) on shares of AveXis in a report on Tuesday, September 5th. Finally, Instinet assumed coverage on shares of AveXis in a report on Tuesday, August 29th. They issued a “reduce” rating and a $52.00 price objective on the stock. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and thirteen have issued a buy rating to the company’s stock. AveXis currently has a consensus rating of “Buy” and an average target price of $99.29.
AveXis, Inc. (NASDAQ:AVXS) opened at 88.08 on Friday. The firm’s market capitalization is $2.81 billion. AveXis, Inc. has a 12 month low of $38.46 and a 12 month high of $99.45. The stock’s 50 day moving average price is $93.12 and its 200-day moving average price is $80.06.
AveXis (NASDAQ:AVXS) last announced its earnings results on Thursday, August 10th. The company reported ($2.07) EPS for the quarter, missing the consensus estimate of ($0.97) by ($1.10). During the same quarter last year, the firm posted ($0.68) earnings per share. On average, analysts forecast that AveXis, Inc. will post ($6.04) earnings per share for the current year.
In other AveXis news, VP Sukumar Nagendran sold 1,780 shares of the firm’s stock in a transaction that occurred on Tuesday, August 1st. The stock was sold at an average price of $91.52, for a total transaction of $162,905.60. Following the completion of the sale, the vice president now owns 1,780 shares in the company, valued at approximately $162,905.60. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last 90 days, insiders have sold 5,340 shares of company stock valued at $474,637. 18.60% of the stock is owned by insiders.
WARNING: This piece of content was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/09/17/avexis-inc-avxs-shares-bought-by-rhumbline-advisers.html.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Want to see what other hedge funds are holding AVXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AveXis, Inc. (NASDAQ:AVXS).
Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.